This evidence, together with the NP-R ability to impair NGB accumulation in cancer cells, prompted us to evaluate the capability of the prodrug to render breast cancer cells more prone to the anticancer effect of the chemotherapeutic drug paclitaxel. This evidence concerns the gene NPTXR and breast carcinoma.